Treatment with Tie2‑siRNA in combination with carboplatin suppresses the growth of Ishikawa human endometrial carcinoma cell xenografts in vivo

Guo,Feifei; Xun,Qingying; Zhou,Huaijun

doi:10.3892/ol.2013.1295

Treatment with Tie2‑siRNA in combination with carboplatin suppresses the growth of Ishikawa human endometrial carcinoma cell xenografts in vivo

Authors:
- Feifei Guo
- Qingying Xun
- Huaijun Zhou
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, P.R. China, Department of Physiology, Medical College, Southeast University, Nanjing, Jiangsu, P.R. China
Published online on: April 8, 2013 https://doi.org/10.3892/ol.2013.1295
Pages: 1777-1782

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is well-known that tumor angiogenesis is important in cancer development, and studies on blocking angiogenesis to treat tumors have become one of the most promising and active ﬁelds in anticancer research. The present study investigated the effect of siRNA targeting the tyrosine kinase receptor 2 (Tie2) gene in combination with carboplatin in a mouse model of endometrial carcinoma in an attempt to elucidate the role of Tie2 in the carcinogenesis and progression of endometrial carcinoma via angiogenesis, in order to establish a basis for the development of complementary molecule targeting and chemotherapeutic actions. Ishikawa cells were used to establish a human endometrial carcinoma nude mouse tumor xenograft model. Tie2‑siRNA (20 µg/mouse) and/or carboplatin (25.0 mg·kg‑1) were administered as the treatment strategy. Real‑time PCR and western blotting were used to evaluate the expression levels of Tie2 mRNA and protein and immunohistochemistry was used to assess the vessel density of the tumor tissues. The present data demonstrated that Tie2‑siRNA and/or carboplatin were able to suppress the growth of endometrial xenografts in vivo and attenuate the expression of Tie2 mRNA and protein, as assessed by real‑time PCR and western blotting. Furthermore, immunohistochemical assessment showed that the vessel density of the tumors decreased with treatment. The present results suggest that treatment with Tie2‑siRNA or carboplatin alone was able to inhibit the growth of human endometrial carcinoma nude mouse xenografts markedly and decrease the expression of Tie2. The combination of Tie2‑siRNA and carboplatin increased the therapeutic effect of carboplatin which may eliminate the tumor microenvironment, increase the apoptosis of tumor cells, normalize the abnormal tumor vessels and increase the efficiency of chemotherapy for endometrial carcinoma with carboplatin. The synergy of Tie2‑siRNA in combination with carboplatin may involve the regulation of other angiogenesis and metastasis pathways.

View Figures

View References

1	National Cancer Institute at the National Institutes of Health: Endometrial Cancer Home Page. http://seer.cancer.gov/statfacts/html/corp.html Accessed November 10, 2010.
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3	Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW: Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 70:367–377. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ray M and Fleming G: Management of advanced-stage and recurrent endometrial cancer. Semin Oncol. 36:145–154. 2009. View Article : Google Scholar : PubMed/NCBI
5	Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and Wong J: Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 9:5339–5345. 2003.PubMed/NCBI
6	Carmeliet P: Angiogenesis in life, disease and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
7	Sistla A, Kertelj A and Shenoy N: Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent). PDA J Pharm Sci Technol. 62:200–210. 2008.PubMed/NCBI
8	Griffioen AW: Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol Immunother. 57:1553–1558. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kimura Y, Sumiyoshi M and Baba K: Anti-tumor actions of major component 3′-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation. Cancer Lett. 265:84–97. 2008.PubMed/NCBI
10	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
11	Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995. View Article : Google Scholar
12	Klauber N, Rohan RM, Flynn E and D’Amato RJ: Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med. 3:443–446. 1997. View Article : Google Scholar : PubMed/NCBI
13	Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin DJ and Kojiro M: Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 7:725–729. 2000.PubMed/NCBI
14	Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
15	Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinicals studies. Cancer Res. 65:671–680. 2005.PubMed/NCBI
16	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
17	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
18	Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M and Tsuneyoshi M: Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol. 56:854–860. 2003. View Article : Google Scholar : PubMed/NCBI
19	Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, Huang HJ, Gunji Y, Nishikawa R, Alitalo K, Cavenee WK and Cheng SY: Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci USA. 100:8904–8909. 2003. View Article : Google Scholar : PubMed/NCBI
20	Yang H, Yang K, Hu JK, Tang H, Zhang B, Chen ZX, Wang YJ and Chen JP: Eukaryotic expression of extracellular ligand binding domains of murine Tie-2 and its anti-angiogenesis effect in SGC-7901 cell lines. J Gastroenterol Hepatol. 25:345–351. 2010. View Article : Google Scholar : PubMed/NCBI
21	Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J and Breitman ML: tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene. 7:1471–1480. 1992.PubMed/NCBI
22	Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W and Qin Y: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:70–74. 1995. View Article : Google Scholar : PubMed/NCBI
23	Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1171–1180. 1996. View Article : Google Scholar : PubMed/NCBI
24	Eklund L and Olsen BR: Tie receptors and their angiopoietin ligands are context-depedent regulators of vascular remodeling. Exp Cell Res. 312:630–641. 2006. View Article : Google Scholar : PubMed/NCBI
25	Mori Y, Sahara H, Matsumoto K, Takahashi N, Yamazaki T, Ohta K, Aoki S, Miura M, Sugawara F, Sakaguchi K and Sato N: Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3′-sulfoquinovosyl-1′-monoacylglycerol, targeting angiogenesis. Cancer Sci. 99:1063–1070. 2008.PubMed/NCBI
26	Mai J, Song S, Rui M, Liu D, Ding Q, Peng J and Xu Y: A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J Control Release. 139:174–181. 2009. View Article : Google Scholar : PubMed/NCBI
27	Yamakawa D, Kidoya H, Sakimoto S, Jia W and Takakura N: 2-Methoxycinnamaldehyde inhibits tumor angiogenesis by suppressing Tie2 activation. Biochem Biophys Res Commun. 415:174–180. 2011. View Article : Google Scholar : PubMed/NCBI
28	Tournaire R, Simon MP, le Noble F, Eichmann A, England P and Pouysségur J: A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep. 5:262–267. 2004. View Article : Google Scholar : PubMed/NCBI
29	Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR and Lampidis TJ: 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64:31–34. 2004. View Article : Google Scholar : PubMed/NCBI
30	Sennino B, Falcón BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM and McDonald DM: Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res. 67:7358–7367. 2007. View Article : Google Scholar : PubMed/NCBI
31	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
32	Devroe E and Silver PA: Therapeutic potential of retroviral RNAi vectors. Expert Opin Biol Ther. 4:319–327. 2004. View Article : Google Scholar : PubMed/NCBI
33	Behlke MA: Chemical modification of siRNAs for in vivo use. Oligonucleotides. 18:305–319. 2008. View Article : Google Scholar : PubMed/NCBI